Focused On-demand Library for Lutropin-choriogonadotropic hormone receptor

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P22888

UPID:
LSHR_HUMAN

ALTERNATIVE NAMES:
Luteinizing hormone receptor

ALTERNATIVE UPACC:
P22888; Q14751; Q15996; Q9UEW9

BACKGROUND:
The Luteinizing hormone receptor plays a critical role in reproductive health, acting as the receptor for lutropin-choriogonadotropic hormone. Its function involves G protein-mediated activation of adenylate cyclase, essential for reproductive processes (PubMed:11847099).

THERAPEUTIC SIGNIFICANCE:
Mutations in this receptor contribute to disorders such as Familial male precocious puberty and Luteinizing hormone resistance, underscoring its therapeutic potential. Exploring this receptor's function could lead to innovative treatments for related reproductive diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.